Researchers led by the University of California, San Francisco (UCSF) developed a blood test that can identify Alzheimer’s disease risk decades before symptoms appear [1].

This development is significant because it allows for the detection of the disease in mid-life adults. Early identification provides a window for medical intervention before cognitive decline becomes clinically apparent [3, 5].

The study, reported in 2024, utilized data from mid-life participants across North America [1, 2]. By measuring specific biomarkers in the blood, the test aims to spot the subtle signs of cognitive decline that precede the more severe stages of the disease [1, 2].

Researchers collaborated with international partners to refine the process [1]. The goal is to create a diagnostic tool that is as accurate as expensive imaging scans, but far more accessible for routine screening [3].

Traditional diagnosis often occurs only after a patient exhibits memory loss or behavioral changes. This new approach focuses on the biological changes in the blood that signal the onset of the disease long before those symptoms manifest [2, 4].

Early detection is viewed as a critical step toward improving patient outcomes. If the disease is identified early, clinicians may be able to implement lifestyle changes, or pharmaceutical treatments, to slow the progression of the condition [5].

“A blood test measuring specific biomarkers can indicate the presence of Alzheimer’s disease decades before clinical symptoms appear.”

The shift toward blood-based biomarkers represents a move away from reactive diagnostics toward proactive screening. By identifying high-risk individuals in mid-life, the medical community can potentially shift the treatment paradigm from managing end-stage dementia to preventing or delaying the onset of cognitive impairment through early intervention.